Dr. Daud reviews ASCO 2016 immunology updates
REGISTER
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

Dr. Daud reviews ASCO 2016 immunology updates

› Forums › General Melanoma Community › Dr. Daud reviews ASCO 2016 immunology updates

  • Post
Viewing 5 reply threads
  • Replies
      • September 8, 2016 at 5:31 pm
      Polymath
      Participant

      Thanks Celeste for this posting.  I was drawn to the Masterkey 265 study of T-Vec combined with PD-1.  I'm on the Nivo long-term now, and my specialist has suggested concurrent T-Vec.  Wow, the numbers look really promising.  I am surprised T-Vec is not discussed more on this board, especially since it's an FDA approved treatment.  I now anxiously await results of my tumor biopsy to at least know if I qualify.  Getting the treatment, because of where I live is another matter altogether though.

      Gary

      • September 8, 2016 at 5:31 pm
      Polymath
      Participant

      Thanks Celeste for this posting.  I was drawn to the Masterkey 265 study of T-Vec combined with PD-1.  I'm on the Nivo long-term now, and my specialist has suggested concurrent T-Vec.  Wow, the numbers look really promising.  I am surprised T-Vec is not discussed more on this board, especially since it's an FDA approved treatment.  I now anxiously await results of my tumor biopsy to at least know if I qualify.  Getting the treatment, because of where I live is another matter altogether though.

      Gary

      • September 8, 2016 at 5:31 pm
      Polymath
      Participant

      Thanks Celeste for this posting.  I was drawn to the Masterkey 265 study of T-Vec combined with PD-1.  I'm on the Nivo long-term now, and my specialist has suggested concurrent T-Vec.  Wow, the numbers look really promising.  I am surprised T-Vec is not discussed more on this board, especially since it's an FDA approved treatment.  I now anxiously await results of my tumor biopsy to at least know if I qualify.  Getting the treatment, because of where I live is another matter altogether though.

      Gary

        • September 8, 2016 at 8:24 pm
        Bubbles
        Participant

        Hey Gary, 

        Yes!!  I have long been a fan of intralesionals (T-VEC and PV10).  Especially when they are combined with immunotherapy.  Hopefully, they will continue to do as well as this study looks!!!  Hang in there!  C

        • September 8, 2016 at 8:24 pm
        Bubbles
        Participant

        Hey Gary, 

        Yes!!  I have long been a fan of intralesionals (T-VEC and PV10).  Especially when they are combined with immunotherapy.  Hopefully, they will continue to do as well as this study looks!!!  Hang in there!  C

        • September 8, 2016 at 8:24 pm
        Bubbles
        Participant

        Hey Gary, 

        Yes!!  I have long been a fan of intralesionals (T-VEC and PV10).  Especially when they are combined with immunotherapy.  Hopefully, they will continue to do as well as this study looks!!!  Hang in there!  C

      • September 8, 2016 at 8:03 pm
      Mat
      Participant

      Thanks Celeste.  I had not seen this stat before for ipi/nivo:

      • BRAF mutant (BRAF positive) patients had a 67% ORR to the combo.  (NOTE:  Previously BRAF status had not been a proven factor in response rate.)
      • September 8, 2016 at 8:03 pm
      Mat
      Participant

      Thanks Celeste.  I had not seen this stat before for ipi/nivo:

      • BRAF mutant (BRAF positive) patients had a 67% ORR to the combo.  (NOTE:  Previously BRAF status had not been a proven factor in response rate.)
      • September 8, 2016 at 8:03 pm
      Mat
      Participant

      Thanks Celeste.  I had not seen this stat before for ipi/nivo:

      • BRAF mutant (BRAF positive) patients had a 67% ORR to the combo.  (NOTE:  Previously BRAF status had not been a proven factor in response rate.)
        • September 8, 2016 at 8:27 pm
        Bubbles
        Participant

        I know, Mat.  At one point years ago, there was some data saying that BRAF status DID affect response rates to immunotherapy.  Then the pendulum shifted as data pointed to no affect on outcomes.  Now this is out.  So….not quite sure what the end result will be…  Hope they'll figure out how to get good results, quickly…for everyone!!!  C

        • September 8, 2016 at 8:27 pm
        Bubbles
        Participant

        I know, Mat.  At one point years ago, there was some data saying that BRAF status DID affect response rates to immunotherapy.  Then the pendulum shifted as data pointed to no affect on outcomes.  Now this is out.  So….not quite sure what the end result will be…  Hope they'll figure out how to get good results, quickly…for everyone!!!  C

        • September 8, 2016 at 8:27 pm
        Bubbles
        Participant

        I know, Mat.  At one point years ago, there was some data saying that BRAF status DID affect response rates to immunotherapy.  Then the pendulum shifted as data pointed to no affect on outcomes.  Now this is out.  So….not quite sure what the end result will be…  Hope they'll figure out how to get good results, quickly…for everyone!!!  C

Viewing 5 reply threads
  • You must be logged in to reply to this topic.
About the MRF Patient Forum

The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

Popular Topics